Genentech
Sangamo Therapeutics and Genentech team up to develop genomic medicines for neurodegenerative diseases
August 7, 2024Research and Development Genentech, Neurology, Sangamo Therapeutics, genomic medicine, neurodegenerative diseases
Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
April 15, 2024Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
Genentech shares positive results from phase 3 trial for breast cancer treatment
December 5, 2023Research and Development Genentech, Oncology, breast cancer, oncology
Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …
Genentech and NVIDIA enter AI research collaboration
November 22, 2023Research and Development AI, Genentech, Pharmacy, research collaboration
Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA that is intended to pair …
Genentech shares data from phase 3 trials of Vabysmo for retinal vein occlusion treatment
October 10, 2023Research and Development Genentech, Opthalmology, Vabysmo, phase 3 trial, retinal vein occlusion
Genentech has announced positive topline long-term results from its global phase 3 BALATON and COMINO trials which assessed extended treatment …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
September 1, 2023Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …
Genentech shares results from phase 3 trial for MS treatment
July 13, 2023Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial
Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …
Genentech’s injectable eye medicine extends time between treatments for two conditions
February 15, 2021Sales and Marketing Genentech
Genentech has announced detailed, positive results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment …
Genentech announces positive top-line results for “wet” age-related macular degeneration antibody
January 25, 2021Sales and Marketing Genentech
Genentech has announced positive top-line results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational …
Genentech’s cancer drug gets Breakthrough Therapy Designation from FDA
January 5, 2021Manufacturing and Production Cancer, Genentech
Genentech has announced that tiragolumab, a novel cancer immunotherapy designed to bind to T cell immunoreceptor with Ig and ITIM …
Genetech scores sixth FDA approval in lung cancer with Gavreto
September 7, 2020Sales and Marketing Cancer, FDA, Genentech, lung cancer
Genentech’s once-daily oral therapy Gavreto (pralsetinib) has secured FDA backing in the treatment of metastatic rearranged during transfection (RET) fusion-positive …
Genentech’s Evrysdi becomes first FDA-approved oral treatment for spinal muscular atrophy
August 10, 2020Sales and Marketing Evrysdi, FDA, Genentech, Roche, spinal muscular atrophy
Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy (SMA), making it the first oral therapy …
UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+
July 30, 2020Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership
UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …
Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer
July 13, 2020Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq
Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …
Latest content
Five Facts about cardiovascular disease
